Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBT (2022 - 2025)

Historic EBT for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$39.6 million.

  • Stoke Therapeutics' EBT fell 4992.43% to -$39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 13826.23%. This contributed to the annual value of -$88.7 million for FY2024, which is 1538.26% up from last year.
  • As of Q3 2025, Stoke Therapeutics' EBT stood at -$39.6 million, which was down 4992.43% from -$23.5 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' EBT ranged from a high of $114.2 million in Q1 2025 and a low of -$39.6 million during Q3 2025
  • Its 4-year average for EBT is -$16.3 million, with a median of -$25.7 million in 2024.
  • The largest annual percentage gain for Stoke Therapeutics' EBT in the last 5 years was 53283.92% (2025), contrasted with its biggest fall of 4992.43% (2025).
  • Quarter analysis of 4 years shows Stoke Therapeutics' EBT stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 270.92% to -$39.6 million in 2025.
  • Its EBT was -$39.6 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $114.2 million in Q1 2025.